Previous 10 | Next 10 |
2024-06-03 17:38:01 ET More on FibroGen Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug Seeking Alpha’...
2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...
2024-05-31 06:49:06 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Regeneron Pharmaceuticals, Inc. (REGN) Q1...
2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...
2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...
2024-05-29 09:27:44 ET More on Biohaven Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge Biohaven drops 4%, prices $230M share offering Biohaven stock slides 15% amid data presentations Seeking Alpha’s Q...
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors PR Newswire -BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstra...
2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...
2024-05-25 10:00:00 ET The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future has in store for us? Regardless of what happens, investing in market lea...
2024-05-24 13:42:55 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics Read the full article on Seeking Alpha ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...